Literature DB >> 29344921

Does simplified quantitative analysis of 18F-FDG PET in cardiac inflammatory disease work?

R Nkoulou1,2, H Zaidi3,4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29344921     DOI： 10.1007/s12350-017-1179-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  25 in total

1.  Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Yoshio Ishida; Keiichiro Yoshinaga; Masao Miyagawa; Masao Moroi; Chisato Kondoh; Keisuke Kiso; Shinichiro Kumita
Journal:  Ann Nucl Med       Date:  2014-01-25       Impact factor: 2.668

Review 2.  A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology.

Authors: 
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2017-10-01       Impact factor: 6.875

3.  Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.

Authors:  T R Wallhaus; M Taylor; T R DeGrado; D C Russell; P Stanko; R J Nickles; C K Stone
Journal:  Circulation       Date:  2001-05-22       Impact factor: 29.690

4.  Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET.

Authors:  Florent Tixier; Mathieu Hatt; Catherine Cheze Le Rest; Adrien Le Pogam; Laurent Corcos; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2012-03-27       Impact factor: 10.057

5.  Inter- and Intraobserver Agreement of 18F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis.

Authors:  Hiroshi Ohira; Brian Mc Ardle; Robert A deKemp; Pablo Nery; Daniel Juneau; Jennifer M Renaud; Ran Klein; Owen Clarkin; Karen MacDonald; Eugene Leung; Girish Nair; Rob Beanlands; David Birnie
Journal:  J Nucl Med       Date:  2017-03-02       Impact factor: 10.057

6.  Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET.

Authors:  Nghi C Nguyen; Jose L Vercher-Conejero; Abdus Sattar; Michael A Miller; Piotr J Maniawski; David W Jordan; Raymond F Muzic; Kuan-Hao Su; James K O'Donnell; Peter F Faulhaber
Journal:  J Nucl Med       Date:  2015-07-09       Impact factor: 10.057

7.  Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis.

Authors:  Fanny Orlhac; Michaël Soussan; Jacques-Antoine Maisonobe; Camilo A Garcia; Bruno Vanderlinden; Irène Buvat
Journal:  J Nucl Med       Date:  2014-02-18       Impact factor: 10.057

8.  Administration of unfractionated heparin with prolonged fasting could reduce physiological 18F-fluorodeoxyglucose uptake in the heart.

Authors:  Atsuro Masuda; Masanao Naya; Osamu Manabe; Keiichi Magota; Keiichiro Yoshinaga; Hiroyuki Tsutsui; Nagara Tamaki
Journal:  Acta Radiol       Date:  2015-09-02       Impact factor: 1.990

9.  Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET.

Authors:  Nicolas A Karakatsanis; Yun Zhou; Martin A Lodge; Michael E Casey; Richard L Wahl; Habib Zaidi; Arman Rahmim
Journal:  Phys Med Biol       Date:  2015-10-28       Impact factor: 3.609

10.  Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis.

Authors:  Michael T Osborne; Edward A Hulten; Avinainder Singh; Alfonso H Waller; Marcio S Bittencourt; Garrick C Stewart; Jon Hainer; Venkatesh L Murthy; Hicham Skali; Sharmila Dorbala; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2013-12-03       Impact factor: 5.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.